TITLE

INCLONE/UCB TO DEVELOP/COMMERCIALIZE CDP-791

PUB. DATE
October 2005
SOURCE
Worldwide Biotech;Oct2005, Vol. 17 Issue 10, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on a worldwide strategic partnership of ImClone Systems Inc. and UCB aimed at the development and commercialization of CDP-791, a novel investigational antibody, as of October 2005. Findings of the Phase I testing undergone by CDP-791; Terms of the partnership; Background information on UCB.
ACCESSION #
18393347

 

Related Articles

  • ImClone, BMS Expanding Erbitux Collaboration.  // Bioworld Week;8/6/2007, Vol. 15 Issue 32, p3 

    The article reports on the collaboration agreement between the New York-based companies ImClone Systems Inc. and Bristol-Myers Squibb Co. (BMS) for the development of anticancer agent Erbitux. Under the terms of agreement, all development costs will be paid by BMS up to a certain threshold and...

  • Opinion: ImClone/UCB: tapping into a rich vein.  // PharmaWatch: Cancer;Oct2005, Vol. 4 Issue 10, p11 

    Focuses on a partnership between ImClone Systems Inc. and UCB Group Ltd. to co-develop an early-stage cancer drug. Terms of the alliance; Renewal of interest in angiogenesis inhibitors; Process of drug approval.

  • Opinion: ImClone/UCB: tapping into a rich vein.  // PharmaWatch: Monthly Review;Oct2005, Vol. 4 Issue 10, p7 

    Focuses on a partnership between ImClone Systems Inc. and UCB Group Ltd. to co-develop an early-stage cancer drug. Terms of the alliance; Renewal of interest in angiogenesis inhibitors; Process of drug approval.

  • Pipeline.  // Medical Marketing & Media;Mar2004, Vol. 39 Issue 3, p10 

    Presents news concerning the drug development market in the United States as of March 2004. Food and Drug Administration approval received by Pfizer Inc. for the dual-therapy medication Caduet; Marketing strategy prepared by ImClone Systems Inc. for the cancer treatment Erbitux.

  • BMS and ImClone Settle Dispute With New Deal.  // Chemical Market Reporter;3/11/2002, Vol. 261 Issue 10, p2 

    Reports on the revision of the terms of the partnership agreement between ImClone Systems Inc. and Bristol-Myers Squibb Co. concerning the cancer drug Erbitux. Payment received by ImClone; Expectations from the deal.

  • ImClone Meets With FDA ANd Plans Erbitux Refiling.  // Chemical Market Reporter;3/4/2002, Vol. 261 Issue 9, p3 

    Reports the partnership of ImClone Systems Inc. and Bristol-Myers Squibb Co. Plan of the company in manufacturing drugs; Data of the clinical trial; Approval of cancer drug.

  • Evotec enters into integrated drug discovery collaboration with UCB.  // PharmaWatch: CNS;Aug2011, Vol. 10 Issue 8, p19 

    The article announces that Evotec AG has entered into a three year integrated discovery collaboration with UCB SA to identify molecule moderators of priority biological targets involved in central nervous system (CNS) disorders.

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Nov2008, Vol. 7 Issue 11, p3 

    The article offers news briefs related to pharmaceutical industry. Eli Lilly & Co. plans to acquire ImClone Systems Inc. for $6.5 billion. FDA has approved Eli Lilly's Alimta for first-line therapy in advanced and metastatic non-small cell lung cancer. UCB company has withdrawn European...

  • Amgen's Trial Of Vectibix Falls Short; ImClone Shares Benefit. Boggs, Jennifer // BioWorld Today;3/26/2007, Vol. 18 Issue 58, p1 

    The article reports on the decision of Amgen Inc. to stop the Phase III trial of its colorectal cancer drug Vectibix and its impact on the shares of rival ImClone Systems Inc. Shares of Amgen declined following its decision to stop the Phase III trial of Vectibix due to lack of efficacy and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics